Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR4 | O95977 | 5/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 4/20 | 0.43 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5103949 | 0.89 | TAAR1 (0.40) | SCN10AROCK2CYP1A2AAK1 | |
| Trifluoroacetic Acid SCHEMBL4157721 | 0.83 | S1PR4 (0.46) | S1PR4S1PR1S1PR5SCN10ASIRT1 | |
| Trifluoroacetic Acid SCHEMBL4156410 | 0.83 | S1PR4 (0.51) | S1PR4S1PR1S1PR5SCN10AOPRM1 | |
| Trifluoroacetic Acid SCHEMBL4154336 | 0.83 | S1PR4 (0.47) | S1PR4S1PR1S1PR5SCN10AROCK2 | |
| Trifluoroacetic Acid SCHEMBL4164102 | 0.83 | S1PR4 (0.47) | S1PR4S1PR1S1PR5SCN10AROCK2 | |
| Trifluoroacetic Acid SCHEMBL4166142 | 0.82 | S1PR4 (0.45) | S1PR4S1PR1S1PR5SCN10AROCK2 | |
| Trifluoroacetic Acid SCHEMBL4144867 | 0.82 | S1PR4 (0.44) | S1PR4S1PR1S1PR5SCN10AOPRM1 | |
| Trifluoroacetic Acid SCHEMBL4146413 | 0.81 | S1PR4 (0.44) | S1PR4S1PR1S1PR5SCN10A | |
| SCHEMBL5794188 | 0.78 | SCN10A (0.45) | SCN10AROCK2SIRT1CYP1A2HDAC6 | |
| SCHEMBL5104251 | 0.76 | AAK1 (0.44) | S1PR4S1PR1S1PR5SCN10ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-7429597-B2 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-09-30 | — | — | US | disclosed |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | F11, F12, F2 | S1PR4 4711/4885S1PR1 3898/4885S1PR5 4042/4885 |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | S1PR4 4618/4885S1PR1 4147/4885S1PR5 4160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.